Fig. 1: Systematic screening analyses identify LAMC2 as a key gene for promoting EGFR TKI sensitivity. | Cancer Gene Therapy

Fig. 1: Systematic screening analyses identify LAMC2 as a key gene for promoting EGFR TKI sensitivity.

From: LAMC2 promotes EGFR cell membrane localization and acts as a novel biomarker for tyrosine kinase inhibitors (TKIs) sensitivity in lung cancer

Fig. 1

A Bioinformatics analysis flowchart. B Cross-screening analyses using CCLE and PRISM identified 53 common genes significantly correlated with high TKI sensitivity in 930 different cancer cell lines. C Principal component analysis using TCGA database showed distinct clusters of these 53 genes in squamous cell carcinoma, adenocarcinoma, and their corresponding control groups. D Analysis using CCLE and Project Achilles data from DepMap (Cancer Dependency Map) portal showed correlation between top ten EGFR-dependent genes. E Volcano plot of gene effect analysis using CCLE and Project Achilles showed top differentially expressed genes associated with EGFR dependence (EGFR-dependent vs. EGFR-independent). F The gene set enrichment analysis (GSEA) indicate LAMC2 is significantly correlated with ERBB and MTOR signaling pathways in lung cancer. G TCGA data comparison of LAMC2 expression in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) patient tumor and normal tissue samples. Red indicates tumor, and gray indicates normal tissue samples. H Kaplan–Meier survival probability curves of LUAD and LUSC patients (TCGA database) with low or high LAMC2 expression levels. I Kaplan–Meier survival probability curves of lung cancer patients with low or high LAMNB2 (LAMC2) expression levels (GEO database).

Back to article page